前列腺特异性抗原密度。在前列腺癌筛查中这个参数有作用吗？
Prostate specific antigen density. Is there a role for this parameter when screening for prostate cancer?
作者信息
Lujan M, Paez A, Llanes L, Miravalles E, Berenguer A
机构信息
Department of Urology, Hospital Universitario de Getafe, Madrid, Spain.
出版信息
Prostate Cancer Prostatic Dis. 2001;4(3):146-149. doi: 10.1038/sj.pcan.4500509.
The objective of this paper is to validate prostate specific antigen (PSA) density (PSAD) routine use to enhance PSA specificity in men with normal digital rectal examination and intermediate PSA values. It is a retrospective study of 235 men from a prostate cancer (PCa) screening program. All of them presented PSA values between 4 and 10 ng/ml, normal digital rectal examination, and a transrectal ultrasound (TRUS) guided biopsy available (PSA>/=4 ng/ml as the sole criterion for biopsy). Multivariate analysis failed to demonstrate higher PSAD values in men with PCa. PSAD cutoff points higher than 0.07 ng/ml per cc were considered as unacceptable, with less than 95% sensitivity. When a cutoff point of 0.15 was considered, as many as 30.6% of the cancers were missed. In conclusion we cannot recommend the use of this parameter for the above mentioned purpose.Prostate Cancer and Prostatic Diseases (2001) 4, 146-149.
本文的目的是验证前列腺特异性抗原（PSA）密度（PSAD）在直肠指检正常且PSA值处于中等水平的男性中常规用于提高PSA特异性的效果。这是一项对来自前列腺癌（PCa）筛查项目的235名男性进行的回顾性研究。他们所有人的PSA值在4至10 ng/ml之间，直肠指检正常，且可进行经直肠超声（TRUS）引导下的活检（PSA≥4 ng/ml作为活检的唯一标准）。多变量分析未能证明患有PCa的男性具有更高的PSAD值。PSAD临界值高于每立方厘米0.07 ng/ml被认为不可接受，敏感性低于95%。当考虑临界值为0.15时，多达30.6%的癌症被漏诊。总之，我们不建议将该参数用于上述目的。《前列腺癌与前列腺疾病》（2001年）4卷，第146 - 149页 。
Zotero 插件